[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-ischemic-stroke-ais-related-to-a-distal-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-ischemic-stroke-ais-related-to-a-distal-occlusion":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100650675","forward-functional-outcomes-in-real-world-treatment-and-revascularization-of-non-dominant-and-distal-m2-occlusions-100650675",false,"NCT07749170","FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions","Inclusion Criteria:\n\n1. Participant age ≥ 18\n2. Participant experiencing acute ischemic stroke due to a confirmed primary M2 occlusion in the vertical segment or post-bifurcation in the non-dominant or co-dominant branch of the horizontal segment\n3. NIHSS ≥5 or NIHSS 3-4 with disabling symptoms\n4. Pre-stroke mRS 0-1\n5. For participants undergoing thrombectomy: Planned first-line treatment with Penumbra System reperfusion catheters\n6. Informed consent obtained per Institutional Review Board\u002FEthics Committee requirements\n\nExclusion Criteria:\n\n1. Any stenosis or occlusion in the ICA origin requiring treatment during the procedure or within the 90-day follow-up period.\n2. Known multiple occlusions\n3. Secondary M2 occlusion\n4. Known or high suspicion of underlying ICAD as the cause of the M2 occlusion\n5. Current hospitalization at time of stroke onset and\u002For any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 90 days\n6. Currently participating in an investigational (drug, device, etc.) clinical trial that will influence the endovascular procedure or acute treatment. Participants in secondary prevention, observational, natural history and\u002For epidemiological studies are eligible.\n7. Other medical, behavioral, or psychological conditions that in the opinion of the Investigator could limit the ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study","ALL","18 Years",{"count":18,"type":19},250,"ESTIMATED","OBSERVATIONAL","The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical thrombectomy (EVT). Additionally, this study aims to observe characteristics and outcomes of participants treated with medical management (MM) alone and those who receive EVT + MM per current medical practice.",[23,24],"Acute Ischemic Stroke","Acute Ischemic Stroke (AIS) Related to a Distal Occlusion","RECRUITING","2026-08-05",{"date":28,"type":29},"2026-08-06","ACTUAL",{"date":31,"type":29},"2026-06-26",{"date":33,"type":19},"2028-09",{"name":35,"class":36},"Penumbra Inc.","INDUSTRY",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100619672","randomized-clinical-trial-of-endovascular-therapy-for-acute-ischemic-stroke-with-occlusion-of-the-m2-segment-of-middle-cerebral-artery-100619672","NCT07347665","Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery","Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery (the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-M2 Occlusion Trial: RESCUE-M2O Trial)","Inclusion Criteria:\n\n1. Acute cerebral infarction\n2. Aged 18-84 years\n3. NIHSS score at admission ≥ 8\n4. Prestroke mRS scores of 0-1 (able to carry out all usual activities)\n5. Occlusion of the M2 segment of MCA on digital subtraction angiography\n6. ASPECTS ≥ 8 or DWI-ASPECTS ≥ 8\n7. Ineligible or failed intravenous tPA (no recanalization within 30 min after injection)\n8. Randomization can be completed within 24 h from the last known well time\n9. EVT can be initiated within 30 min from randomization.\n10. The patient or their legally authorized representative has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Occlusion of the anterior temporal artery, duplicate M1, or accessory M1\n2. Occlusion of multiple major intracranial arteries\n3. Difficulty in endovascular access due to tortuous vascular anatomy\n4. Significant mass effect with midline shift on CT (or MRI)\n5. Known allergy (more severe than skin rash) to contrast agents\n6. Evidence of acute intracranial hemorrhage on CT (or MRI)\n7. Pregnant or potentially pregnant\n8. Clinical evidence of chronic occlusion\n9. High risk of hemorrhage (platelet \\\u003C 40,000\u002Ful, APTT \\> 50 sec or PT-INR \\> 3.0)\n10. Participating in any other therapeutic investigational trial\n11. Judgment of the investigator to be non-compliant or uncooperative during the study","84 Years",{"count":47,"type":19},200,"INTERVENTIONAL",[50],"NA","RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.",[53,23,24],"Endovascular Therapy","2026-07-15",{"date":56,"type":29},"2026-07-17",{"date":58,"type":29},"2025-12-01",{"date":60,"type":19},"2030-03-31",{"name":62,"class":63},"Hyogo Medical University","OTHER",3]